We recently compiled a list of the 12 Best Long-Term Stocks to Buy According to Ken Fisher. In this article, we are going to ...

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...

Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its ...

Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say ...

Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Strategic Financial Concepts LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 67.7% during the fourth quarter, according to the company in its most recent filing ...

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...

But these nitpickers miss the big picture. Splits matter - because these stocks outperform after the announcement, by a lot. Average returns one year later are 25% vs. 12% for the S&P 500 SPX as a ...